- Home
- HYB vs PBYI Comparison
HYB vs PBYI Comparison
Compare HYB & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYB
- PBYI
- Stock Information
- Founded
- HYB 1987
- PBYI 2010
- Country
- HYB United States
- PBYI United States
- Employees
- HYB N/A
- PBYI N/A
- Industry
- HYB Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- HYB Finance
- PBYI Health Care
- Exchange
- HYB Nasdaq
- PBYI Nasdaq
- Market Cap
- HYB 191.2M
- PBYI 153.2M
- IPO Year
- HYB 1999
- PBYI N/A
- Fundamental
- Price
- HYB $8.23
- PBYI $3.09
- Analyst Decision
- HYB
- PBYI Strong Buy
- Analyst Count
- HYB 0
- PBYI 1
- Target Price
- HYB N/A
- PBYI $7.00
- AVG Volume (30 Days)
- HYB 39.6K
- PBYI 754.5K
- Earning Date
- HYB 01-01-0001
- PBYI 02-27-2025
- Dividend Yield
- HYB 6.67%
- PBYI N/A
- EPS Growth
- HYB N/A
- PBYI 492.79
- EPS
- HYB N/A
- PBYI 0.47
- Revenue
- HYB N/A
- PBYI $243,569,000.00
- Revenue This Year
- HYB N/A
- PBYI N/A
- Revenue Next Year
- HYB N/A
- PBYI N/A
- P/E Ratio
- HYB N/A
- PBYI $6.63
- Revenue Growth
- HYB N/A
- PBYI 6.30
- 52 Week Low
- HYB $6.23
- PBYI $2.23
- 52 Week High
- HYB $7.41
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- HYB 51.78
- PBYI 49.17
- Support Level
- HYB $8.14
- PBYI $2.92
- Resistance Level
- HYB $8.29
- PBYI $4.06
- Average True Range (ATR)
- HYB 0.07
- PBYI 0.29
- MACD
- HYB 0.01
- PBYI 0.01
- Stochastic Oscillator
- HYB 66.67
- PBYI 27.07
About HYB New America High Income Fund Inc. (The)
New America High Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide high current income while seeking to preserve stockholder capital by investing in a diversified portfolio of high-yield fixed-income securities. The Fund has a leveraged capital structure. The fund invests in fixed-maturity corporate debt securities that are rated less than the investment grade. Its portfolio of investment consists of investments in different sectors such as energy, financial, cable operators, healthcare, and others.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.